Why this lab-grown human embryo has reignited an old ethical debate
By Patrick Monahan,
Science/AAAS
| 05. 04. 2016
[citing CGS' Marcy Darnovsky]
Untitled Document
It’s easy to obey a rule when you don’t have the means to break it. For decades, many countries have permitted human embryos to be studied in the laboratory only up to 14 days after their creation by in vitro fertilization. But—as far as anyone knows—no researcher has ever come close to the limit. The point of implantation, when the embryo attaches to the uterus about 7 days after fertilization, has been an almost insurmountable barrier for researchers culturing human embryos.
Now, two teams report growing human embryos about a week past that point. Beyond opening a new window on human biology, such work could help explain early miscarriages caused by implantation gone awry. As a result, some scientists and bioethicists contend that it’s time to revisit the so-called 14-day rule. But that won’t be welcomed by those who consider the rule to have a firm moral grounding—or by those who oppose any research on human embryos.
“We’re here sooner than we thought,” says Insoo Hyun, a bioethicist at the School of Medicine at Case Western Reserve University...
Related Articles
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...